MedTrace Logo

Bimatoprost as a Treatment for Graves' Orbitopathy

NCT03708627 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-07-17

No results posted yet for this study

Summary

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Conditions

  • Graves Ophthalmopathy

Interventions

DRUG

Bimatoprost Ophthalmic

Bimatoprost, aka Lumigan, one drop in one eye nightly

Sponsors & Collaborators

Principal Investigators

  • Emily Li, MD · Johns Hopkins University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2029-07-01
Completion
2031-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03708627 on ClinicalTrials.gov